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Abstract: Although patients with non-alcoholic fatty liver disease (NAFLD) face a higher risk of
cardiovascular disease (CVD), it is not known whether people with NAFLD are less likely to achieve
optimal management of low-density lipoprotein (LDL) cholesterol than those without NAFLD. We
aimed to investigate the longitudinal effect of NAFLD on the management of LDL cholesterol in
5610 adults from the Korean Genome and Epidemiology Study. Participants were classified into
NAFLD and normal groups. Non-achievement of the target LDL cholesterol level was set according
to one’s cardiovascular disease (CVD) risk level. The estimated proportion of individuals who did not
achieve their LDL cholesterol targets was higher in the NAFLD group than in the normal group during
the follow-up period of 12 years in a generalized estimation equation model. Multivariable Cox
regression analysis revealed a hazard ratio and 95% confidence interval for incident non-achievement
of one’s LDL cholesterol target of 1.196 (1.057–1.353) in the NAFLD group (p = 0.005). We found that
NAFLD was significantly related to non-achievement of LDL cholesterol targets in this prospective
cohort study. Prevention and proper management of NAFLD have important health implications for
the prevention of CVD.
Keywords: non-alcoholic fatty liver disease; low-density lipoprotein cholesterol; cardiovascular disease
1. Introduction
Cardiovascular disease (CVD) is a major cause of morbidity and mortality world-
wide [1]. According to the 2017 World Health Organization fact sheet, approximately 31%
of all deaths (17.9 million people) stemmed from CVD in 2016 [2]. Risk factors for CVD
can be classified into non-modifiable and modifiable risk factors. Non-modifiable risk
factors include age, sex, ethnicity, and family history of premature coronary artery disease;
modifiable risk factors include smoking, diabetes, high blood pressure, obesity, physical
inactivity, and high blood cholesterol. Individuals who are at high risk or have already
experienced CVD are recommended to manage modifiable CVD risk factors, including
behavioral factors [3–5]. Among the modifiable metabolic risk factors, low-density lipopro-
tein (LDL) cholesterol is a well-known risk factor for the development of atherosclerosis [6].
To reduce CVD risk as much as possible, current guidelines recommend optimizing LDL
cholesterol management based on an individual’s CVD risk level [3,6,7].
The liver plays a major role in lipid metabolism [8]. Non-alcoholic fatty liver disease
(NAFLD), including non-alcoholic steatohepatitis and liver cirrhosis, has become the most
common cause of chronic liver disease worldwide [9]. NAFLD is usually accompanied by
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metabolic disorders, such as type 2 diabetes, obesity, and dyslipidemia [10]. Therefore, the
risk of CVD among NAFLD patients is likely to be higher than it is in normal individuals.
Interestingly, a longitudinal follow-up study showed that the most common cause of death
in NAFLD patients is cardiovascular disease (CVD), not liver-related disease [11]. Thus, a
multidisciplinary patient-centered and personalized medicine approach might be needed
to effectively prevent CVD in NAFLD patients. However, there is no evidence on whether
people with NAFLD are less likely to achieve optimal management of LDL cholesterol than
people without NAFLD.
Therefore, in this study, we aimed to investigate the effect of NAFLD on the manage-
ment of LDL cholesterol based on one’s CVD risk.
2. Materials and Methods
2.1. Study Population
We used data from the Korean Genome and Epidemiology Study (KoGES) (known
as the KoGES_Ansan and Ansung study). The KoGES_Ansan and Ansung study is a
longitudinal prospective cohort study initiated by the Korean National Institute of Health
to verify risk factors for non-communicable diseases [12]. A total of 10030 community-
dwellers aged 40–69 years in urban (Ansan) and rural (Ansung) areas were recruited in
the baseline survey (2001–2002). The survey was conducted biennially up to 2013–2014
(sixth follow-up).
From the 10030 participants in the baseline survey, we excluded those who (1) had a
history of hepatitis (n = 423), (2) consumed ≥30 g of alcohol per day in men or ≥20 g per
day in women (n = 964), (3) had no data with which to calculate NAFLD liver fat scores
(n = 276), (4) had no data with which to evaluate LDL cholesterol targets according to
individual CVD risk (n = 276), and (5) achieved their LDL cholesterol target at the baseline
survey (n = 2193). Of the remaining 6174 participants, 564 participants who had no follow-
up data after the baseline survey were further excluded. Finally, a total of 5610 participants
(1131 participants with NALFD and 4479 participants without NAFLD) were analyzed in
the study (Figure 1). Informed consent was obtained from all eligible participants. This
study was approved by the Institutional Review Board (IRB) of Yongin Severance Hospital
(IRB number: 9-2020-0043).
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2.2. Assessment of NAFLD
NAFLD was defined using the previously validated fatty liver prediction model, the
NAFLD-liver fat score, with the following formula: −2.89 + 1.18 × metabolic syndrome
(Yes: 1, No: 0) + 0.45 × diabetes mellitus (Yes: 2, No: 0) + 0.15 × insulin in µIU/mL + 0.04
× AST in U/L–0.94 × aspartate aminotransferase (AST)/alanine aminotransferase (ALT).
An NAFLD-liver fat score > −0.640 was considered indicative of having NALFD [13].
2.3. Assessment of LDL Cholesterol Target Levels According to CVD Risk
LDL cholesterol levels were calculated using the Friedewald equation for participants
with serum triglyceride levels less than 400 mg/dL as follows: LDL cholesterol (mg/dL) =
total cholesterol − high-density lipoprotein (HDL) cholesterol − (triglyceride/5) [14].
The major risk factors for CVD included five items: (1) men aged ≥ 45 years and
women aged ≥ 55 years; (2) systolic blood pressure (SBP) ≥ 140 mmHg and diastolic blood
pressure (DBP) ≥ 90 mmHg or current treatment with antihypertensive medications for
more than 20 days per month; (3) current smoker; (4) HDL cholesterol level < 40 mg/dL;
and (5) family history of premature CVD developing before the age of 55 years in men and
before the age of 65 years in women among an individual’s parents and/or siblings. HDL
cholesterol ≥ 60 mg/dL was considered as a protective factor for CVD risk [7].
We categorized the participants into four risk groups (low risk, moderate risk, high
risk, and very high risk) based on their total CVD risk level. Participants who had no or
one CVD risk factor (among the major five risk factors for CVD) were classified into the
low-risk group. The moderate-risk group comprised participants with two or more major
risk factors for CVD. Participants with diabetes mellitus without signs of target organ
damage were classified into the high-risk group. The very high-risk group consisted of (1)
participants who had experienced coronary artery disease, ischemic stroke, or transient
ischemic attack; (2) patients with diabetes with signs of target organ damage (glomerular
filtration rate < 60 mL/min/1.73 m2, albuminuria, concurrence of hypertension); or (3)
diabetic patients who were current smokers.
The LDL cholesterol management target levels according to each individual’s CVD risk
level were set as LDL cholesterol level < 160 mg/dL for the low-risk group, <130 mg/dL
for the moderate-risk group, <100 mg/dL for the high-risk group, and <70 mg/dL for the
very high-risk group, respectively [7].
Finally, we defined non-achievement of LDL cholesterol target as a higher LDL choles-
terol level than the LDL cholesterol management targets based on one’s CVD risk.
2.4. Covariates
Height (m) and body weight (kg) were measured to the nearest 0.1 cm and 0.1 kg,
respectively. Body mass index (BMI) was calculated as body weight divided by height
squared (kg/m2). Waist circumference (WC) was measured in the horizontal plane midway
between the lowest rib and the iliac crest (cm). Obesity was defined as a BMI ≥ 25 mg/m2
according to the diagnostic criterion for obesity defined by the Korean Society for the Study
of Obesity [15]. SBP and DBP were defined as the average of the last two of three measured
values taken at 5-min intervals. Mean blood pressure (MBP) was then calculated using the
equation (SBP + 2 × DBP)/3.
All blood tests were performed after at least 8 hours of overnight fasting. Plasma glu-
cose level, serum concentrations of total cholesterol, triglyceride, and HDL cholesterol, AST,
and ALT were measured enzymatically using a Chemistry Analyzer (Hitachi 7600, Tokyo,
Japan by August 2002 and ADVIA 1650, Siemens, Tarrytown, NY from September 2002). C-
reactive protein (CRP) concentrations were measured by means of an immunoradiometric
assay (ADVIA 1650, Siemens, Tarrytown, NY, USA).
History of smoking status, drinking status, employment status, and monthly income
were collected during an interview. A current smoker was defined as one who smokes
currently and has smoked at least 100 cigarettes during his/her lifetime. We divided alcohol
drinking status into two categories: currently drinking or not. We also calculated the
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amount of alcohol intake consumed by the participants according to the number of grams
of alcohol consumed per day (g/day). We regarded one episode of exercise as exercise for at
least 30 min [16]. Then, we categorized physical activity into two groups: regular exercise
(more than three episodes per week) or not (less than two episodes per week). Employment
status was divided into two groups: employed and unemployed. Monthly income was
categorized into three groups: less than one million Korean Won, 1–2 million Korean Won,
and more than 2 million Korean Won. We defined the presence of chronic diseases as having
at least one of comorbid conditions such as chronic obstructive pulmonary disease or any
chronic cancer, excluding other chronic diseases (diabetes mellitus, stroke, myocardial
infarction, and chronic kidney disease stages 3 to 5) used to assess the LDL cholesterol
management target level.
For dietary surveillance, a validated food frequency questionnaire (FFQ) consisting
of 103 food items was used [17,18]. Daily total calorie intake (kcal/day), protein intake
(g/day), fat intake (g/day), and carbohydrate intake (g/day) were calculated through
the FFQ.
2.5. Statistical Analysis
All data are presented as numbers (percentages, %) for categorical variables and
means ± standard deviations (SD) or medians (25th, 75th) for continuous variables. For
continuous variables, the independent t-test or Mann–Whitney U-test were performed to
compare differences between the two study groups. The Chi-squared test was used to
compare categorical variables. We used a generalized estimation equation (GEE) to assess
the long-term effects of NAFLD, while considering correlations between measurements
over time. The cumulative incidence of non-achievement of LDL cholesterol target was rep-
resented by Kaplan–Meier curves. The log-rank test was used to determine if distributions
of the cumulative incidence of non-achievement of LDL cholesterol target differed between
groups. Multivariable Cox proportional hazards regression models were used to calculate
hazard ratios (HRs) and 95% confidence intervals (CIs) for incident non-achievement of
LDL cholesterol targets after adjusting for potential confounding variables. Subgroup
analyses for age group, sex, obesity status, physical activity, smoking status, and alcohol
drinking status were also performed.
All statistical analyses were conducted using SAS statistical software (version 9.4; SAS
Institute Inc., Cary, NC, USA) and R (Version 4.0.3; R Foundation for Statistical Computing,
Vienna, Austria). The significance level was set at p < 0.05.
3. Results
3.1. General Characteristics of the Study Population
The baseline characteristics of the study population are shown in Table 1. Among
all 5610 participants, 1131 (20.2%) had NAFLD. The proportion of male was significantly
higher in the NAFLD group than the normal group. The mean age ± SD was 51.8 ± 8.8
in the normal group and 52.9 ± 8.6 in the NAFLD group (p < 0.001), respectively. The
mean BMI, WC, MBP, serum total cholesterol, and LDL cholesterol levels; as well as the
the median values of plasma glucose level, serum insulin, triglyceride, AST, ALT, CRP
levels, homeostasis assessment model of insulin resistance (HOMA-IR); and changes in
LDL cholesterol level per year were significantly higher in the NAFLD group than in the
normal group. The mean value of the HDL cholesterol level was significantly lower in
the NAFLD group. The prevalence of obesity and diabetes mellitus and the proportion of
monthly income less than 1 million Korean Won were higher in the NAFLD group. The
proportion of individuals at moderate risk, high risk, and very high risk for CVD were
significantly higher in the NAFLD group than the normal group.
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Table 1. Baseline characteristics of the study population.
KoGES: Ansan_Ansung Study
Normal NAFLD p
Numbers (n) 4479 1131
Male, n (%) 1716 (38.3) 495 (43.8) 0.001
Age, years 51.0 ± 8.8 52.9 ± 8.6 <0.001
Waist circumference, cm 79.6 ± 8.2 88.8 ± 7.8 <0.001
BMI, kg/m2 23.8 ± 2.8 26.5 ± 3.0 <0.001
Obesity, n (%) 1124 (25.1) 591 (52.3) <0.001
Mean blood pressure, mmHg 90.4 ± 12.3 99.7 ± 12.1 <0.001
Glucose, mg/dL 81 (76, 85) 84 (78, 92) <0.001
Insulin, µU/mL 6.4 (4.9, 8.4) 10.4 (8.1, 13.0) <0.001
HOMA-IR 1.3 (1.0, 1.7)) 2.2 (1.7, 2.8) <0.001
Total cholesterol, mg/dL 178.9 ± 27.6 187.6 ± 32.4 <0.001
Triglyceride, mg/dL 116 (90, 154) 201 (152, 283) <0.001
HDL cholesterol, mg/dL 46.0 ± 10.0 39.3 ± 8.6 <0.001
LDL cholesterol, mg/dL 103.1 ± 26.2 106.4 ± 24.1 <0.001
Changes in LDL cholesterol level,
mg/dL/year 3.0 (0.6, 8.4) 4.7 (0.9, 15.0) <0.001
AST, IU/L 25 (22, 29) 29 (24, 36) <0.001
ALT, IU/L 20 (16, 26) 31 (22, 45) <0.001
CRP, mg/dL 0.1 (0.1, 0.2) 0.2 (0.1, 0.3) <0.001
Monthly household income, n (%) <0.001
<1 million Korean Won 1476 (33.6) 446 (40.6) <0.001
1–2 million Korean Won 1400 (31.8) 295 (26.9) 0.001
>2 million Korean Won 1522 (34.6) 357 (32.5) 0.191
Employment status, n (%) 2432 (54.7) 631 (56.4) 0.314
Regular exercise, n (%) 2223 (51.3) 529 (48.5) 0.101
Current smoker, n (%) 832 (18.9) 236 (21.2) 0.074
Current drinker, n (%) 1917 (43.2) 449 (40.1) 0.062
Daily amount of alcohol intake, g/day 5 (2, 12) 8 (3, 18) <0.001
Daily caloric intake, kcal/day 1820 (1500, 2198) 1860 (1534, 2291) 0.022
Daily carbohydrate intake, g/day 322 (275, 382) 333 (284, 405) <0.001
Daily protein intake, g/day 61 (47, 77) 61 (48, 78) 0.554
Daily fat intake, g/day 28 (19, 40) 27 (17, 39) 0.016
Chronic diseases, n (%) * 136 (3.0) 34 (3.0) 0.960
Diabetes mellitus, n (%) 22 (0.5) 105 (9.3) <0.001
CVD risk group, n (%) <0.001
Low risk group 3113 (69.5) 440 (38.9) <0.001
Moderate risk group 1337 (29.9) 582 (51.5) <0.001
High risk group 16 (0.4) 34 (3.0) <0.001
Very high risk group 13 (0.3) 75 (6.6) <0.001
Abbreviations: NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; HOMA-IR, homeostasis assess-
ment model of insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; CRP, C-reactive protein; CVD, cardiovascular disease. * Chronic
disease was defined as having at least one of the following: chronic obstructive pulmonary disease or any chronic
cancers. Data are presented as means ± standard deviations or medians (interquartile range). p was calculated
using the independent t-test or Mann–Whitney U-test for continuous variables and the Chi-squared test for
categorical variables.
3.2. Proportion of Non-Achievement of LDL Cholesterol Targets According to NAFLD Status
Considering the Effect of Time
Table 2 shows the prediction of time effects on the proportion of non-achievement of
LDL cholesterol targets according to NAFLD status using GEE models. In both overall and
post-hoc analysis, the estimated proportions of non-achievement of LDL cholesterol targets
in the NAFLD group remained higher than those in the normal group during all follow-up
periods. The group × time interactions were also statistically significant.
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Table 2. Generalized estimating equation models predicting the effects of time on the proportion of non-achievement of
LDL cholesterol targets according to NAFLD status.
Normal NAFLD
Time Estimated Proportion (%) SE Estimated Proportion (%) SE Overall p Post-Hoc p






2nd f/u 18.77 0.637 30.54 1.500 <0.0001
3rd f/u 22.13 0.715 33.60 1.605 <0.0001
4th f/u 28.03 0.770 41.41 1.702 <0.0001
5th f/u 21.21 0.722 27.72 1.593 0.0002
6th f/u 22.27 0.749 28.53 1.657 0.0006
Abbreviations: LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease; SE, standard error. group×time means interactions
between group and time.
3.3. Longitudinal Association between NAFLD and LDL-Cholesterol Target Out Events
A total of 2819 (50.3%) participants experienced non-achievement of their LDL choles-
terol targets. The cumulative incidences of non-achievement of LDL cholesterol targets
according to NAFLD status are presented in Figure 2 as Kaplan–Meier curves. The NAFLD
group had higher cumulative incident non-achievement of LDL cholesterol targets than
the normal group over 12 years of follow-up with significance (log-rank test p < 0.001).
Int. J. Environ. Res. Public Health 2021, 18, x FOR PEER REVIEW 6 of 13 
 
 
3.2. Proportion of Non-Achievement of LDL Cholesterol Targets according to NAFLD Status 
Considering the Effect of Time 
Table 2 shows the prediction of time effects on the proportion of non-achievement of 
LDL cholesterol targets according to NAFLD status using GEE models. In both overall 
and post-hoc analysis, the estimated proportions of non-achievement of LDL cholesterol 
targets in the NAFLD group remained higher than those in the normal group during all 
follow-up periods. The group × time interactions were also statistically significant. 
Table 2. Generalized estimating equation models predicting the effects of time on the proportion of non-achievement of 
LDL cholesterol targets according to NAFLD status. 
 Normal NAFLD   
Time Estimated Proportion (%) SE 
Estimated Proportion 
(%) SE Overall p Post-hoc p 
1st f/u 17.91 0.588 32.32 1.421 
group: < 0.001 
time: < 0.001 
group×time: 0.0005 
<0.0001 
2nd f/u 18.77 0.637 30.54 1.500 <0.0001 
3rd f/u  22.13 0.715 33.60 1.605 <0.0001 
4th f/u 28.03 0.770 41.41 1.702 <0.0001 
5th f/u 21.21 0.722 27.72 1.593 2 
6th f/u 22.27 0.749 28.53 1.657 0.0006 
Abbreviations: LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease; SE, standard error. group×time 
means interactions between group and time.  
3.3. Longitudinal Association between NAFLD and LDL-Cholesterol Target Out Events 
A total of 2819 (50.3%) participants experienced non-achievement of their LDL cho-
lesterol targets. The cumulative incidences of non-achievement of LDL cholesterol targets 
according to NAFLD status are presented in Figure 2 as Kaplan–Meier curves. The 
NAFLD group had higher cumulative incident non-achievement of LDL cholesterol tar-
gets than the normal group over 12 years of follow-up with significance (log-rank test p < 
0.001). 
 
Figure 2. Cumulative incidence of non-achievement of LDL cholesterol targets according to 
NAFLD status. Abbreviations: LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver 
disease. 
Table 3 shows the independent relationships between NAFLD status and non-
achievement of LDL cholesterol targets over a 12-year follow-up period. The HR with a 
95% CI for non-achievement of LDL cholesterol targets in the NAFLD group, compared 
Figure 2. Cumulative incidence of non-achievement of LDL cholesterol targets according to NAFLD
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Table 3 shows the independent relationships between NAFLD status and non- achieve-
ment of LDL cholesterol targets over a 12-ye r follow-up period. The HR wi h a 95% CI f r
non-achiev ment of DL chol sterol targets in the NAFLD gr up, compared to the normal
group, was 1.718 (1.578–1.870, p < 0.001). Simila ly, a longitudinal association was noted af-
ter additional adjustment for age, sex, BMI, regular exercise, current smoker status, current
drinker status, MBP, daily caloric intake, plasma glucose level, serum total cholesterol level,
serum ALT level, serum CRP level, chronic diseases, treatment with anti-dyslipidemic
medications, and changes in LDL cholesterol level per year. The corresponding adjusted
HR with a 95% CI was 1.196 (1.057–1.353, p = 0.005).
Figure 3 shows the results of subgroup analyses (age group, sex, obesity status,
physical activity, smoking status, and alcohol drinking status) of the relationship between
NAFLD status and non-achievement of LDL cholesterol targets, presented as HRs with 95%
CI values. After adjusting for all potential confounding variables, except for each subgroup
variable, there were significant associations between NAFLD and incident non-achievement
of LDL cholesterol targets in the subgroup of individuals younger than 65 years in both
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sex subgroups, in both non-obesity and obesity subgroups, in both non-regular exercise
and regular exercise subgroups, in non-smokers, and in non-drinkers, whereas older age,
current smokers, and current drinkers did not show a significant relationship.
Table 3. Relationship between NAFLD status and non-achievement of LDL cholesterol targets.
Unadjusted Adjusted *
HR (95% CI) p HR (95% CI) p
NAFLD (vs. Normal) 1.718 (0.578–1.870) <0.001 1.196 (1.057–1.353) 0.005
Male (vs. Female) 1.007 (0.933–1.086) 0.866 1.253 (1.114–1.410) <0.001
Age (per 1 increment) 1.020 (1.016–1.024) <0.001 1.020 (1.015–1.026) <0.001
BMI (per 1 increment) 1.072 (1.058–1.086) <0.001 1.030 (1.014–1.047) <0.001
Regular exercise (vs. non-regular exercise) 0.957 (0.888–1.031) 0.247 0.931 (0.852–1.019) 0.120
Current smoker (vs. ex-/non-smoker) 1.132 (1.031–1.243) 0.010 1.412 (1.231–1.620) <0.001
Current drinker (vs. non-drinker) 1.124 (1.042–1.212) 0.003 1.262 (1.139–1.398) <0.001
Mean blood pressure (per 1 increment) 1.014 (1.012–1.017) <0.001 1.007 (1.003–1.011) <0.001
Daily caloric intake (per 1 increment) 1.000 (1.000–1.000) 0.113 1.000 (1.000–1.000) 0.361
Glucose (per 1 increment) 1.008 (1.007–1.010) <0.001 1.010 (1.005–1.015) <0.001
Total cholesterol (per 1 increment) 1.017 (1.016–1.018) <0.001 1.019 (1.017–1.021) <0.001
ALT (per 1 increment) 1.002 (1.001–1.002) <0.001 1.000 (0.999–1.001) 0.718
CRP (per 1 increment) 1.056 (0.996–1.120) 0.069 1.137 (1.006–1.284) 0.040
Chronic diseases (vs. without chronic diseases) 1.071 (0.871–1.317) 0.514 1.043 (0.814–1.336) 0.741
Anti-dyslipidemic medications
(vs. without anti-dyslipidemic medications) 2.061 (1.140–3.725) 0.017 0.358 (0.155–0.823) 0.016
Changes in LDL cholesterol level per year (per 1 increment) 1.089 (1.086–1.092) <0.001 1.087 (1.083–1.091) <0.001
Abbreviations: NAFLD, non-alcoholic fatty liver disease; LDL, low-density lipoprotein; HR, hazard ratio; CI, confidence interval;
BMI, body mass index; ALT, alanine aminotransferase; CRP, C-reactive protein. * Adjusted for age, sex, BMI, regular exercise, current
smoker status, current drinker status, mean blood pressure, daily caloric intake, plasma glucose level, serum total cholesterol level, serum
ALT level, serum CRP level, chronic diseases, treatment with anti-dyslipidemic medications, and changes in LDL cholesterol level per year.
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that NAFLD is significantly related with an increased risk of fatal and non-fatal cardio-
vascular events. Wu et al. [24] showed that NAFLD is associated with an increased risk of 
major adverse cardiovascular events, but not with all-cause mortality or CVD mortality. 
Another meta-analysis [25] found that NAFLD is associated with increased all-cause mor-
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than individuals without NAFLD after considering possible confounders. In the subgroup 
analysis, similar results were shown regardless of sex, obesity, and regular exercise. Alt-
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Figure 3. Subgroup analysis for associations between NAFLD and non-achievement of LDL targets. Abbreviations: NAFLD,
non-alcoholic fatty liver disease; LDL, low-density lipoprotein; BMI, body mass index; ALT, alanine aminotransferase;
CRP, C-reactive protein. Results were adjusted for age, sex, BMI, regular exercise, current smoker status, current drinker
status, mean blood pressure, daily caloric intake, serum ALT level, serum CRP level, chronic diseases, treatment with
anti-dyslipidemic medications, and changes in LDL cholesterol level per year except for each subgroup variable.
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4. Discussion
We found that patients with NAFLD experienced unfavorable management of LDL
cholesterol using data collected from a large-sample prospective cohort study in Korea.
In NAFLD, dyslipidemia is characterized by elevated triglyceride and LDL cholesterol
and decreased HDL cholesterol [19]. Atherogenic dyslipidemia could increase the CVD
risk in NAFLD patients. Previous studies have noted that NAFLD itself is a novel and
independent risk factor of CVD. In a large multi-ethnic cohort, NAFLD was shown to be
associated with higher triglyceride and LDL particle concentrations and lower LDL particle
size and HDL cholesterol, independently of insulin resistance [20]. Hamaguchi et al. [21]
showed that NAFLD, defined by ultrasonography, was a significant predictor of cardio-
vascular events after adjusting for conventional cardiovascular risk factors in Japanese
men and women. In addition, Targher et al. [22] found that the risk of CVD events were
significantly higher in diabetic individuals with NAFLD than in diabetics without NAFLD
after adjusting for sex, age, smoking, diabetes duration, hemoglobin A1c, LDL cholesterol,
medications, and metabolic syndrome (odds ratios: 1.87 (95% CIs: 1.20–2.60), p < 0.001).
These results suggest that NAFLD increases the CVD risk independently of the presence of
conventional risk factors (e.g., age, diabetes mellitus, and metabolic syndrome).
Several meta-analyses have sought to reveal associations between NAFLD, CVD risk,
and mortality, although results have been inconsistent [23–25]. Targher et al. [23] found that
NAFLD is significantly related with an increased risk of fatal and non-fatal cardiovascular
events. Wu et al. [24] showed that NAFLD is associated with an increased risk of major
adverse cardiovascular events, but not with all-cause mortality or CVD mortality. Another
meta-analysis [25] found that NAFLD is associated with increased all-cause mortality, but
not with CVD mortality or cancer mortality.
We found that fewer patients with NAFLD achieved their LDL cholesterol targets
than individuals without NAFLD after considering possible confounders. In the subgroup
analysis, similar results were shown regardless of sex, obesity, and regular exercise. Al-
though the estimated proportion of individuals that did not achieve their LDL cholesterol
targets would vary with time, this proportion was higher in the NAFLD group than in the
normal group throughout the entire 12-year follow-up period. Indeed, the difference in
this proportion between groups decreased with time (group × time interaction p = 0.0005).
Even in the normal group without NAFLD at the baseline survey, metabolic diseases such
as NAFLD, metabolic syndrome, and diabetes mellitus could occur in the group over time,
which could lead to a decrease in the difference of the estimated proportion of participants
with non-achievement of LDL cholesterol targets between the groups. Time-dependent
Cox proportional regression analysis should be performed considering the occurrence of
NAFLD over time in future research. In subgroup analysis, similar results were observed
regardless of sex, obesity, and regular exercise, which suggests that no interaction was
present in those variables.
Interestingly, a population-based study in the United States reported that the use of
lipid-lowering drugs, including statins, was not associated with overall and CVD mortality
in patients with NAFLD [26]. The authors suggested that the underuse of anti-dyslipidemic
drugs in NAFLD patients with dyslipidemia might be related to this result. They also
suggested that other CVD risk factors, including diabetes and smoking, could have a
greater impact on CVD mortality in NAFLD patients. Our findings could support this
previous report. Altogether, we showed that NAFLD patients did not reach their optimal
LDL management target levels after adjusting for the use of anti-dyslipidemia medication.
This means that NAFLD might confer an excess risk above underlying metabolic risk
factors. However, these findings are in contrast with the results of three post hoc analyses
of randomized controlled trials [27]. The data from the post hoc analyses suggested
that statin treatment reduced CVD morbidity and mortality in NAFLD/NASH patients.
Thus, the effect of lipid-lowering drugs on mortality in NAFLD patients remains to be
established. Other pathogenic abnormalities that increase mortality in NAFLD patients
should be considered in future studies.
Int. J. Environ. Res. Public Health 2021, 18, 3442 9 of 12
There is the possibility of information bias in our study because the proportion of
participants who responded that they had taken anti-dyslipidemic medications was strik-
ingly low (0.3%) at the baseline survey, and 11.7% of the participants responded that
they had taken anti-dyslipidemic medications during the follow-up period. Follow-up
studies should be performed considering time-varying proportions of participants with
anti-dyslipidemic medications to verify the effect of anti-dyslipidemic medications in
NAFLD patients. In addition, there is a lack of information about the specific type of
anti-dyslipidemic medications in the KoGES data. In the baseline survey from 2001 to
2002, it is possible that respondents were relatively unaware of whether they were taking
anti-dyslipidemic medications. Although lipid-lowering treatment should be intensified,
especially in groups with a high CVD risk and with a very high CVD risk according to
current guidelines [7,28], prior guidelines on the management of dyslipidemia, which set
the LDL cholesterol level goal below 100 mg/dL in coronary heart disease (CHD), and the
equivalent CHD risk assessment made doctors prescribe anti-dyslipidemic medications
less than they do now [29].
A few possible mechanisms may underlie our results. The first is insulin resistance
induced by NAFLD. NAFLD occurs when the amount of triglyceride synthesis in the liver
exceeds the amount of triglyceride expenditure [30], and de novo lipogenesis increases [31].
In NAFLD, hepatic glucose production and insulin sensitivity are impaired [32]. Insulin
resistance contributes to an increase in circulating LDL cholesterol levels by upregulating
hepatic lipase and protein convertase subtilisin/kexin type 9 (PCSK9) [33,34]. Second,
hepatic steatosis damages cell-surface LDLR by inducing de novo PCSK9 expression in
mice [35]. The expression of sterol response element binding protein-1c (SREBP-1c), a major
regulator of fatty acid synthesis, has been shown to be higher in NAFLD patients [36].
LDL receptor (LDLR) gene expression has been found to be lower in patients with NAFLD
compared to those without NAFLD [37]. Furthermore, research has indicated that LDLR
gene expression does not differ in NAFLD patients on or off statins [38]. Third, excessive
production of free fatty acids could also be an important factor influencing both the
development of NAFLD and non-achievement of LDL cholesterol management. In the
liver, the activation of transcription factors, such as carbohydrate responsive element
binding protein (ChREBP) and SREBP-1c, helps to synthesize fatty acids in the liver by
interacting with the delivery of chylomicron cholesterol from the intestinal lumen, which
contributes to NAFLD [39]. A portion of chylomicron is incorporated into very-low-density
lipoprotein particles, the source of plasma LDL cholesterol, which may act as a factor
that interferes with the management of LDL cholesterol [40]. Fourth, NAFLD has been
shown to be associated with increased SREBP-2 maturation, 3-hydroxy-3-methylglutaryl
coenzyme A (HMG CoA) reductase expression, and decreased phosphorylation of HMG
CoA reductase [38]. Altogether, these results suggest that disrupted cholesterol metabolism
in NAFLD may lead to increased CVD risk.
In this study, the association between NAFLD and the non-achievement of LDL
cholesterol targets disappeared in subgroups of individuals older than 65 years, current
smokers, and current drinkers. These factors (aging, smoking, and alcohol drinking) might
act as more powerful confounders in the management of LDL cholesterol than NAFLD.
This study has several limitations. First, participants were diagnosed with NAFLD us-
ing a biomarker-based prediction model, the NAFLD liver fat score, rather than using imag-
ing tests or histologic findings. Therefore, we investigated the association between NAFLD
using another surrogate marker (hepatic steatosis index, HSI) and non-achievement of LDL
cholesterol targets. Although it was not statistically significant, the non-achievement of LDL
cholesterol target tended to be associated with NAFLD status using HSI (Tables S1 and S2).
Further studies are needed to analyze the management of LDL cholesterol according to
the severity of fatty liver disease based on imaging tests or liver biopsy. Second, we could
not exclude causes of secondary fatty liver, including autoimmune hepatitis, Wilson’s
disease, and medication-induced fatty liver, due to the lack of data. To overcome this
limitation, however, we excluded heavy alcoholics as well as individuals who had a history
Int. J. Environ. Res. Public Health 2021, 18, 3442 10 of 12
of hepatitis infection, hepatitis B viral infection, or hepatitis C viral infection, which account
for a major proportion of chronic liver diseases in Korea [41]. Third, we could not assess
the potential effect of changes in hepatic steatosis over time on the association between
NAFLD and CVD risk. In the next study, we will further analyze the association between
the non-achievement of LDL cholesterol targets and NAFLD regarding the changes in
NAFLD status (regression group, transient remission group, and persistent group), as in the
previous study [42]. Fourth, we assessed CVD risk levels by applying Korean guidelines
and thus our results may not be applicable to other countries. In addition, the lack of
information on carotid artery stenosis, peripheral artery disease, and abdominal aortic
aneurysm in the KoGES may have led to the underestimation of major CVD risk factors
among the participants. To the best of our knowledge, however, this is the first study to
report on the longitudinal effect of NAFLD on the management of LDL cholesterol levels
in the consideration of an individual’s overall CVD risk. In addition, this relationship
remained significant independently of sex and obesity.
5. Conclusions
We found that NAFLD was significantly associated with non-achievement of LDL
targets in a population-based prospective study. Our results suggest that prevention and
proper management of NAFLD have important health implications for the prevention
of CVD.
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